study question: Do TNF-308 and -238 polymorphisms impact the embryo implantation rate after in vitro fertilization (IVF) in women without female infertility factor? summary answer: The presence of the TNF-308A allele is associated with high implantation and multiple pregnancy rates in women without known infertility factors after ovarian hyperstimulation with exogenous FSH.
Introduction
There is general agreement within the field that multiple pregnancy represents one of the major health risks for in vitro fertilization. These risks are mainly related to prematurity associated with low birthweight and intrauterine growth retardation (Chauhan et al., 2010) . Multiple gestations have been shown to frequently occur after the use of Assisted Reproductive Technologies (ART) in US clinics (Jungheim et al., 2010) , and they represent 21% of all deliveries in Europe (de Mouzon et al., 2010) . The use of single embryo transfer (SET), rather than double embryo transfer (DET), has been proposed as a simple way to prevent these risks (De Sutter et al., 2002; Pinborg, 2005) . Initial trials that explored the use of SET and DET confirmed the decrease in and almost disappearance of twin pregnancies (Pandian et al., 2009) , but the debate has focused on the selection criteria of the patients for SET (Sifer et al., 2010) and on the decrease in pregnancy rates caused by the procedure. Indeed, the extension of SET indications to patients who are not selected based on specific criteria is controversial because of the possible decrease in pregnancy rates (van Montfoort et al., 2006) . To date, criteria used to predict implantation success have included age, gynecological history of the patient and uterine characteristics (i.e. uterine malformation, thickness and vascularization). However, the predictive value of these parameters allows a clinical pregnancy rate after multiple transfer of only 30% (Macklon et al., 2006) . SET is appropriate for women with a good prognosis such as age below 35 years, more than one top-quality embryo, first or second treatment cycle and previous successful IVF (ASRM, 2012) . Several biomarkers, including age, Day-3 FSH and E2 plasma levels, antral follicle count and anti mullerian hormone (AMH), can assess a good prognosis (for a review, see George and Kamath, 2010) . The age-related decline in fecundity for woman is well known (Piette et al., 1990; O'Connor et al., 1998; Chuang et al., 2003) . The decline usually starts at the age of 32 with a dramatic fall after the age of 37. Age is potentially the single most important factor since it evaluates ovarian reserve, and reflects the quality and quantity of oocytes (Chuang et al., 2003) . Older women tend to produce lesser number of oocytes and the embryos have lower implantation potential (George and Kamath, 2010) . Concerning FSH, elevated Day-3 levels predict a low oocyte yield and poor IVF success (Martin et al., 1996; Roberts et al., 2005) . Day-3 plasma E2 levels have the same type of predictive value as FSH (Broekmans et al., 2006) . Finally, AMH together with antral follicle count is considered the better predictors of the ovarian reserve (Schimberni et al., 2009; La Marca et al., 2010) . The different biomarkers used for elective SET (e-SET) tend to evaluate ovarian function and embryo quality as the uterus of women over 40 years has been reported to present similar embryo implantation rates compared with that of younger women (under 35 years) (Check et al., 2010) . However, these criteria do not take into account the individual variability of patients.
One practical approach to evaluate variability between women is the use of single nucleotide polymorphisms (SNPs), particularly of genes involved in the embryo implantation process. Indeed, the availability of a large number of SNPs has opened the possibility of association studies between SNPs and various diseases (Rodriguez-Murillo and Greenberg, 2008) , such as type I and II diabetes, coronary heart disease, breast and prostate cancer and infertility. An association between the FSH-R680 SNP and the amount of FSH required for adequate ovarian stimulation during the course of an IVF procedure has been reported in women with normal ovarian function (Simoni et al., 2002) . The implantation process requires the interaction of the embryo and the endometrium, which needs to be receptive. Endometrium receptivity is an active process, limited in time, which involves the regulation of the expression of hundreds of genes. In the 1990's, the T helper 1 (Th1)/T helper 2 (Th2) cells paradigm was developed and suggested that several inflammatory cytokines have negative effects on materno-fetal relations (Wegmann et al., 1993) . Th1 cytokines, including TNF, were identified as harmful to the foeto-placenta unit by activating uterine natural killer (uNK) cells. More recently, several publications have challenged the Th1/Th2 paradigm by demonstrating that NK cells are required for successful pregnancy (for a review see Chaouat et al., 2007) , that local inflammation promotes implantation (Gnainsky et al., 2010) and that a positive correlation was observed between cytokine (such as TNF) expression in endometrial biopsies (Gnainsky et al., 2010) or secretion (Boomsma et al., 2009) and embryo implantation. Thus the expression of inflammation associated T helper cytokines, such as TNF, could be favorable during the preimplantation and implantation period, particularly since TNF induces shedding of MUC1 which is linked to embryo implantation and of MMP-9 expression which is one of the key enzymes in trophoblast invasion (Haider and Knofler, 2009 ). Nevertheless, exaggerated secretion of Th1 cytokines, such as TNF or IL1, as occurs upon amniotic infection, is known to have a detrimental effect on intrauterine tissues such as abortion (Haider and Knofler, 2009) . During the implantation process, leukemia inhibiting factor (LIF) is necessary, as shown in mice, but other cytokines such as interleukins, TNF, CSF1 and GM-CSF are also involved (for a review see, Chaouat et al., 2007) . In particularly, TNF has been identified in endometrial stroma and glands and at the embryo-maternal surface (Payan-Carreira et al., 2011) . In women, the involvement of TNF remains unclear since on one hand, the cytokine has been linked to an increased rate of spontaneous abortion (Giacomucci et al., 1994) and its levels are increased in follicular fluid from women with endometriosis (Falconer et al., 2009) , while on this other hand, the induction local injury has been associated with successful implantation (Gnainsky et al., 2010) suggesting that the inflammatory response and expression of cytokines such as TNF may facilitate the preparation of the endometrium for implantation (Gnainsky et al., 2010) . Similarly, in endometrial secretions, high levels of cytokines including TNF have been linked to clinical pregnancy (Boomsma et al., 2009) .
Some genetic factors may impact TNF levels, and several polymorphisms in the TNF gene cluster have been associated with modified TNF production (Hajeer and Hutchinson, 2001 ). The TNF gene cluster is located within the class III region of the highly polymorphic major histocompatibility complex on chromosome 6p21, and lies between the lymphotoxin (LTA) and LTB genes (Nedwin et al., 1985) . There are many polymorphisms within the TNF gene cluster. To date, six SNPs have been described in the 5 ′ region of the gene, including -238A/G (rs361525) and -308G/A (rs1800629) SNPs. The commonly studied TNF-308A SNP is part of an extended MHC haplotype HLA-A1-B8-DR3-DQ2, which is associated with high TNF production (for a review see, Wilson et al., 1997) . The TNF-308 polymorphism has a functional significance since the -308A allele is a much more powerful transcriptional activator than the common G allele (Wilson et al., 1997) . Moreover, stimulated peripheral blood mononuclear cells have shown higher (6-to 7-fold increase) TNF production when -308A allele is present (Wilson et al., 1997) . The mechanism involved may result in a differential binding of nuclear factors, within the -323 to -285 sequence from the -308A allele (for a review see, Abraham and Kroeger, 1999) . Finally, the association between the -308A allele and susceptibility to various diseases is suggestive of the polymorphism being functionally relevant in vivo (Abraham and Kroeger, 1999) . The reported frequency of the A allelic type varies greatly in the different populations, from 0% (Hohjoh et al., 1999) to 51.3% (Yucesoy et al., 2002) . In French studies, the frequency of TNF-308 SNP appears to be 25%. Importantly, these studies are related to specific pathologies, including nonHodgkin's lymphoma (Warzocha et al., 1998) , coronary heart disease (Herrmann et al., 1998) , pneumoconiosis (Nadif et al., 2003) , metabolic syndrome (Meirhaeghe et al., 2005) and male infertility (Tronchon et al., 2008) . Another G versus A transition in the promoter region at position -238 has also been shown to influence TNF expression. This region contains a strong repressor site at -280 to -172 (Fong and Mark, 1995) . In different studies, the TNF-238A allele has been associated with decreased TNF production (D'Alfonso and Richiardi, 1994; Kaluza et al., 2000) . Thus the TNF-308 and -238 SNPs might have opposite effects, indeed; the frequency of the TNF-308 A allele was higher, whereas the frequency of the -238 A allele was lower, in lung cancer patients, when compared with controls (Shih et al., 2006) . Therefore, in this study we evaluated the implantation rate in women with and without TNF polymorphisms (-308 and -238) during the course IVF procedures that were conducted due to male infertility factors alone.
Materials and Methods

Participants and recruitment
For this study, two patient populations have been built: the entire patient group contained 424 women, and from among this group, the selected group of 120 patients was formed. The exclusion criteria were the same for the two (entire and selected population) groups: uterine malformation, previous chemotherapy treatment, grade III or IV endometriosis, unilateral ovariectomy or maternal diethylstilbestrol exposure. The entire population group was selected based on one major criterion: women who required an intracytoplasmic sperm injection (ICSI) procedure due to male fertility factors without the contribution of any female factor. More stringent inclusion criteria were used for the selected population group, including a normal karyotype, age under 38 years, serum FSH levels below 10 IU/l on Day 3 of the procedure, severe sperm alterations requiring an ICSI procedure, a unique long agonist desensitization protocol associated with recombinant FSH treatment for ovarian stimulation and Caucasian background. Before the ICSI procedure, patients from both groups underwent an extensive evaluation, including familial and personal history, physical and hysterosalpingographic evaluation, Day 3-hormonal profiles (FSH, LH and E2) and karyotyping. For each patient, a blood sample was collected for DNA analysis. For the ART procedures, follicular maturation was induced with recombinant FSH (GonalFw from Merck Serono, Geneva, Switzerland or Puregonw from MSD, Hoddesdon, United Kingdom) and monitored by E2 measurements and transvaginal ultrasound starting on Day 5. Ovulation was induced with 10 000 UI of recombinant human chorionic gonadotrophin (hCG; Ovitrellew from Merck Serono, Geneva, Switzerland). Transvaginal ultrasound-guided aspiration of follicles was performed 36 h later and the retrieved matured oocytes were fertilized by using intracytoplasmic sperm injection 3 -4 h later. Embryos were cultured for 2 days according to our standard procedures. Day 2 embryo scoring was performed according to Steer's criteria (Steer et al., 1992) , including morphological grade and blastomere number. At 2 -3 days after oocyte retrieval, endometrium thickness was evaluated and 1 -3 embryos were transferred.
This study was conducted according to the Declaration of Helsinki for Medical Research involving Human Subjects and the Ethics Committee. The Medical Review Board of the ART center approved the protocol. Informed consent was obtained for all patients.
TNF genotyping
Genomic DNA was extracted from the blood samples using the Wizardw Genomic DNA Purification kit (Promega, Southampton, UK). Primer pairs F 1 (5 ′ TCTCGGTTTCTTCTCCATCG) and R 1 (5 ′ ATAGGTTTTGAGGG GCATGG) and F 1 -R 2 (5 ′ ATAGGTTTTGAGGGGCATGA) were used to amplify a 184 bp fragment of the TNF gene, which included the polymorphic site at the nucleotic position -308. Each sample was tested with both primer pairs (F 1 -R 1 and F 1 -R 2 ). Primer pair F 1 -R 3 (5 ′ GAGTCTCCGGGTCA GAATGA) was used to amplify a 531 bp TNF gene fragment, which was used as an internal control in the Allele-Specific Polymerase Chain Reaction (ASPCR). Primer R 3 was also used as a competitor for the primer pairs F 1 -R 1 and F 1 -R 2 to improve the specificity of the ASPCR assay (Zhu and Clark, 1996) . After initial heating at 958C for 10 min, 30 PCR cycles were performed as follows: denaturation (958C for 90 s), annealing (628C for 150 s) and extension (728C for 60 s). PCR products were analyzed on agarose gels. As a control experiment, we developed a second approach based on the use of primer F1, (5 ′ ATAGGTTTTGAGGGGCATGG), F2 (5 ′ ATAGGTTTTGA GGGGCATGA) and R (5 ′ TGAAACTTAAGAGCTTTGTGAGTCC). Forward primers were fluorescently labeled with hexachlorocarboxyfluorescein (HEX; green) for F1 and 6-carboxyfluorescein (6-FAM; blue) for F2. After initial heating at 15 min at 958C, 24 PCR cycles were performed as follows: denaturation (948C for 30 s), annealing (658C for 90 s) and extension (728C for 60 s). PCR products were analyzed using the Applied Biosystems 3100 Genetic Analyzer and GENEMAPPERw IDv.3.1 software (Applied Biosystems, Carlsbad, California). All experiments were repeated at least twice for testing the reproducibility of the assay.
For the TNF-238 SNP, a TNF-R primer (5 ′ TCTCGGTTTCTTC TCCATGG) was used with either a 238-G (5 ′ GAAGACCCCCCTCG-GAACCG) or 238-A (5 ′ GAAGACCCCCCTCGGAATCA) primer to amplify a 115 bp fragment, which included the polymorphic site. The primer pair TNF-F (5 ′ GAGTCTCCGGGTCAGAATGA)/TNF-R was used to amplify a 533 bp fragment that was used as an internal control in the ASPCR. The accession numbers were rs1800629 and rs361525 for the -308 and -238 TNF SNPs, respectively.
Statistical analysis
The Mann -Whitney U-test was used to analyze age, FSH, LH, E2, rFSH number units, E2 serum levels 2 days before oocytes retrieval, endometrium thickness, number of mature oocytes, transferred embryos and embryo score, based on the presence or absence of the -308A or -238A TNF allelic types. The Fisher test was used to analyze fertilization, cleavage, embryo implantation, pregnancy, miscarriage and take home baby rates according to the presence or absence of the -308A or -238A TNF allelic types. Statistical tests with a P-value ,0.05 were considered to be statistically significant.
Results
The distribution of the TNF-308A polymorphism was not different in the selected group (23.3%; n ¼ 120) compared with the entire patient group (24.3%; n ¼ 424). In the selected patient group, the TNF-308 polymorphism had no impact on the clinical-biological parameters, including age, basal hormonal pattern, ovarian stimulation treatment and response, amount of exogenous FSH administered, endometrium thickness, number of retrieved oocytes, number of mature oocytes injected with spermatozoa, fertilization rate and cleavage embryo rate (Table I) . However, the E2 plasma levels measured at Day 3 were slightly yet significantly (P ¼ 0.0144) higher in patients with the TNF 308A allele (Table I) . Moreover, the TNF polymorphism was found to be discriminative for the embryo implantation rate (Table II) , which increased from 15.7 to 38.1% in patients with the TNF-308A allele (P ¼ 0.0003). These findings were consistent with the rate of multiple pregnancy, which increased from 5.7 to 29.2% when TNF-308A was present (Table II ; P ¼ 0.0037). Consistently, an increased pregnancy rate (27.1 versus 50.0% for TNF-308G and TNF-308A, respectively; P ¼ 0.0239) and increased take home baby rate (19.6 versus 50.0% for TNF-308G and TNF-308A, respectively; P ¼ 0.0014) were observed in patients with the TNF-308A allele. The increased take home baby rate was also associated with a decrease in the number of miscarriages for patients with the TNF-308A allele (28.0 versus 0% for TNF-308G and TNF-308A, respectively; P ¼ 0.0367). It should be mentioned that the increase in the implantation rate was observed in the absence of any change in embryo quality and endometrium thickness in both SNP populations (Table I) . Taken together, these findings clearly indicate that in patients with the TNF-308A allele, there is an increase in embryo implantation rate with a subsequent increase in pregnancy and take home baby rates. In this selected population, the TNF-308A allele might be a potential biomarker of implantation rate since Day-3 FSH levels and age did not discriminate between implantation and no implantation in these patients (Supplementary data, Table SI). Therefore, based on these findings, we next assessed whether a similar conclusion could be reached in the entire patient group.
As observed for the selected population, the clinical-biological parameters in the entire patient group were similar for patients with the TNF-308A and TNF-308G alleles, with the exception of basal E2 and FSH levels (Table III) . Indeed, in the entire patient group, E2 levels were higher for TNF-308A patients (52.7 pg/ml) compared with patients with TNF-308G (44.8 pg/ml, P ¼ 0.0432), while the basal FSH levels were lower in TNF-308A patients compared with TNF-308G patients (6.64 versus 7.5 UI/l, respectively; P ¼ 0.0387; Table III ). Concerning the implantation status, we found comparable results in the entire group (Table IV) . Indeed, an increase in the embryo implantation rate (13.6 versus 20.6% for TNF-308G and TNF-308A, respectively; P ¼ 0.0146) and a subsequent increase in the multiple pregnancy rate (4.9 versus 11.8% for TNF-308G and TNF-308A, respectively; P ¼ 0.0238) were observed in patients with the TNF-308A allele. However, the previously observed significant increase in pregnancy rate was not observed in patients with the TNF-308A allele in the entire group assessment (Table IV) . In the entire population group, Day-3 FSH levels did not discriminate between for embryo implantation and no implantation, contrary to TNF-308A allele measurement (Supplementary data, Table SII ). As expected, since patient age spanned from 21.7 to 43.7 years, women under 34 years had a significantly higher implantation rate than patients over 34 years (Supplementary data, Table SII ). Finally, in both patient populations, no difference was observed in the implantation rate when frozen and thawed embryos were used for transfer in patients with either allele (Table V) .
A similar experiment was conducted for the TNF-238 A/G polymorphism as well. The distribution of the TNF-238A allele was not different in the selected group compared with the entire group (12.7 versus 11.7%, respectively). The clinical-biological parameters were similar for patients with the TNF-238A and TNF-238G alleles in both the selected and entire patient groups (Tables VI and VII) . Implantation rates were similar between patients with the TNF-238A and G alleles in the selected (21.0 versus 18.5% for TNF-238G and TNF-238A, respectively; Table VI ) and entire patient (15.4 versus 14.2% for TNF-238G and TNF-238A, respectively; Table VII) groups.
Discussion
The aim of this study was to identify (a) potential genetic marker(s) of implantation rate by studying two SNPs (-308 and -238) of the TNF gene in female members of infertile couples. In this context, we identified a group of women without any known female infertility factors who required an ICSI procedure due to severe alterations of sperm in the male partner (entire patient group; n ¼ 424). A population group (selected group; n ¼ 120), which included more strict inclusion criteria with regard to fertility, was also assessed.
The data analysis of the TNF-238 polymorphism showed no difference in clinical-biological parameters and ART data (implantation and pregnancy rates) between the TNF-238A and TNF-238G alleles. It is noteworthy that the TNF-238A allele decreases TNF production (Huizinga et al., 1997; Kaluza et al., 2000) , and TNF-238G allele has been associated with predisposition to the development of psoriasis (Nedoszytko et al., 2007) and advanced lung cancer (Shih et al., 2006) .
The major findings of this study indicate that in the presence of the TNF-308A allele, the implantation and multiple pregnancy rates were increased in both patient groups. Such an increase was observed in the absence of any difference in embryo quality and endometrium thickness. Consistently, in the selected patient group, the increase in embryo implantation rate was accompanied by an increase in the pregnancy rate. In the entire patient group, while an increase in implantation rate was identified in TNF-308A patients, we did not observe the expected significant increase in the pregnancy rate, which might possibly be explained by a lack of statistical power. Moreover, the design of the present study is mainly based on the primary question as to whether TNF polymorphism may impact the implantation rate, evaluating the endometrial function under cytokine action. However, the absence of difference in pregnancy rate in the entire population group may possibly be explained by other factors that may impact the pregnancy rate in this group. Nevertheless, our present observations raise the question as to whether TNF may exert a positive role in the embryo implantation process and whether the TNF-308 SNP may represent a genetic marker of this action.
It is now accepted, based on in vivo studies, that the TNF-308 polymorphism is associated with increased TNF expression and production (Wilson et 1999). TNF may be involved at different steps before and during physiological implantation through its pro-inflammatory activities (van Mourik et al., 2009) . Indeed, local inflammatory responses are initiated in the endometrium during implantation because of the invasive nature of the blastocyst, which results in the production of pro-inflammatory cytokines (Haider and Knofler, 2009) . One of the most important pro-inflammatory cytokines extensively investigated is TNF (Boomsma et al., 2009; Almog et al., 2010; Gnainsky et al., 2010) . The production of this cytokine reaches a maximal level in endometrial epithelial cells during the late secretory phase (Tabibzadeh et al., 1999; Rosario et al., 2005) . Moreover, TNF mediates its inflammatory activities through the induction of luteal prostaglandins (Kowalczyk et al., 2008) that are known to stimulate progesterone production and promote the corpus luteum, which maintains pregnancy through the continuous production of progesterone. TNF pro-inflammatory activities may also be consistent with local injury of the endometrium inducing an inflammatory response that promotes successful implantation (Barash et al., 2003; Almog et al., 2010; Gnainsky et al., 2010) . Interestingly, TNF induces MUC1 (Thathiah et al., 2004) and MMP9 (Meisser et al., 1999) both of which are linked to the embryo implantation process, while its expression may be associated with MIP-1B levels. Expression of both TNF and MIP-1B has been previously identified during the window of implantation (Haider and Knofler, 2009 ). After local injury, an increase in TNF expression is associated with elevated levels of MIP-1B. Therefore, it has been suggested that TNF favors the recruitment of macrophages/dendritic cells to the site of implantation through MIP-1B. These cells trigger the uterine epithelium to produce molecules that facilitate apposition and attachment of the blastocyst to the endometrium. For successful IVF, it has been proposed that an invasive procedure that induces local injury of endometrium is needed, since an inflammation-like process is required to increase TNF expression (Li and Hao, 2009) . It should also be noted that our present observation concerns women undergoing IVF procedures (i.e. conditions of ovarian stimulation due to exogenous FSH administration), and that an association between modification of the implantation window duration and aberrant gene expression has been observed (Barash et al., 2003; Haouzi et al., 2009) . In particular, an increase in various cytokines, such as TNF, in endometrial secretions has been observed in women undergoing IVF procedures. These changes are dependent upon the amplitude of the hyperstimulation (Horcajadas et al., 2008) . Ovarian stimulation is associated with elevated E2 levels, which may exert deleterious effects on embryo implantation, with changes in the endometrial expression pattern compared with normal cycles (Horcajadas et al., 2004) and changes in cytokine levels in endometrial secretions (Boomsma et al., 2009) . The positive role of TNF-308A allele on implantation rate may possibly be explained by several positive actions of TNF. Indeed, TNF could be favorable during the preimplantation and implantation period since it induces shedding of MUC1, which is linked to embryo implantation (Thathiah et al., 2004) and expression of MMP-9, one of the key enzymes in trophoblast invasion (for review see Haider and Knofler, 2009) . TNF is an important regulator of trophoblastic MMPs 2 (Meisser et al., 1999) and 9 (Meisser et al., 1999; Cohen et al., 2006) , both of which mediate the invasion of Matrigel by trophoblastic cells (Staun-Ram et al., 2004) . Studies on knock-out mice have shown that TNF may act as a protector of embryos exposed to teratogenic stress (Toder et al., 2003) . TNF has also been reported to increase the expression of LIF (Arici et al., 1995) and IL6 (Semer et al., 1991) , both of which are well known to be associated with higher embryo implantation rates.
Finally, we also hypothesize that during IVF, which is a nonphysiological situation, TNF may counteract the negative effects of E2, resulting of ovarian stimulation, on the endometrium and may thereby favor the implantation process. Indeed, TNF modulates estrogen biosynthesis in ovary (Sakumoto et al., 2003) and in human endometrial glandular cells (Salama et al., 2009) . To support this hypothesis, we compared the implantation rates after transfer of thawed embryos (i.e. under conditions with mild FSH stimulation) in patients with the two different TNF-308 alleles and found no differences in the implantation rates. Under these conditions, the E2 levels were lower than with fresh embryo transfer, and the TNF polymorphism had no impact on the implantation rate of the entire or select patient groups. Morphological aspects of the embryo do not seem to be modified by the polymorphism, although we cannot exclude an influence of the SNP on the embryo itself.
In conclusion, our results suggest an association between the TNF-308A allele and a high implantation rate. These data indicate that the TNF-308 polymorphism may be a potential non-invasive biomarker of high implantation rate during the course of IVF procedures. Our data suggest that TNF-308 SNP evaluation may help in the SET strategy in women without female infertility factor; however, more studies are needed to extend our results to patients with female infertility. In this context, one of the major challenges in the ART procedures is to reduce the multiple pregnancy risk without compromising the pregnancy rate. For this purpose, the e-SET is the most obvious strategy to use. However, despite published evidence for SET efficiency, the global acceptance of this procedure has been variable in various countries due to a different risk perception and lack of individual objective criteria, which leads to a lack of consensual attitude among physicians (Maheshwari et al., 2011) . Accordingly, the use of genotyping approaches for the identification of potential predictive, non-invasive biomarkers could be helpful for the eSET strategy as patients bearing the TNF-308A allele may represent good candidates for this procedure.
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